Letter from CGS to members of the California Institute for Regenerative Medicine's Independent Citizens Oversight Committee
By Marcy Darnovsky
| 02. 02. 2005
Dear Members of the Independent Citizens Oversight Committee:
The California public has given you the responsibility to oversee
an enormous undertaking of great potential: the largest state-funded
research program in U.S. history. The Center for Genetics and
Society supports the public funding of embryonic stem cell research
but is concerned that the new California Institute for Regenerative
Medicine (CIRM) is off to a stumbling start with regard to public
transparency and accountability. Although these are not due
to explicit decisions by your committee, you are in a position
to remedy them.
There are three particularly troubling areas of concern.
Conflict of interest regulations. This week the National
Institutes of Health - in many ways a federal analogy to your
own enterprise - announced that it is significantly strengthening
its regulations to curtail conflicts of interest. This highlights
a growing awareness that the conduct and oversight of biomedical
research requires strict protections. Yet the ICOC is failing
to make this a priority. Although it is mandated to adopt standards
"initially based" on those of the NIH for its employees
and...
Related Articles
By Rob Stein, NPR | 09.30.2025
Scientists have created human eggs containing genes from adult skin cells, a step that someday could help women who are infertile or gay couples have babies with their own genes but would also raise difficult ethical, social and legal issues...
By Aleks Krotoski, The Guardian | 09.28.2025
Imagine you’re the leader of one of the most powerful nations in the world. You have everything you could want at your disposal: power, influence, money. But, the problem is, your time at the top is fleeting. I’m not...
By Gregory Laub and Hannah Glaser, MedPage Today | 08.07.2025
In this MedPage Today interview, Leigh Turner, PhD, a professor of health policy and bioethics at the University of California Irvine, unpacks the growing influence of stem cell clinics and the blurred line between medicine and marketing. He explains how...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...